Esperoct FDA Approval History
Last updated by Judith Stewart, BPharm on May 19, 2020.
Esperoct (turoctocog alfa pegol, N8-GP) is an extended half-life factor VIII molecule for the treatment of adults and children with hemophilia A.
Development timeline for Esperoct
|Feb 19, 2019||Approval FDA Approves Esperoct (turoctocog alfa pegol, N8-GP) for Hemophilia A|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.